Thanos Zomas, MD, from Takeda Oncology, discusses 5-year follow-up data from the ECHELON-2 study presented at ASH 2020.

The ECHELON-2 study was a double-blind, randomized, multicenter, phase 3 clinical trial that finished in 2018. It compared the efficacy and safety of brentuximab vedotin in combination with cyclophosphamide, doxorubicin, and prednisone (CHP) with the standard-of-care cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) in patients with peripheral T-cell lymphomas. 

Peripheral T-cell lymphomas is a diverse group of aggressive lymphomas that develop from T-cells and natural killer (NK) cells. Peripheral T-cell lymphomas are a subtype of non-Hodgkin’s lymphoma and result when T-cells develop and grow abnormally.

The ECHELON-2 study demonstrated a significantly longer progression-free survival (PFS) and overall survival (OS) in patients receiving brentuximab vedotin+CHP. Median PFS was 48 months in the brentuximab vedotin+CHP group and 21 months in the CHOP group. Adverse events were similar between groups. 

The 5-year follow-up data presented at ASH 2020 reaffirms these results, demonstrating that frontline treatment with brentuximab vedotin+CHP continues to provide clinically meaningful improvement in PFS and OS compared to CHOP.

For more information about peripheral T-cell lymphoma and other rare cancers, visit